Cargando…

Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide with a five-year survival rate of around 25%, and 4% when diagnosed at a metastatic stage. Cancer stem cells (CSC) have recently been characterized as being responsible for resistance to radio/chemotherapies and metasta...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouriez, Damien, Giraud, Julie, Gronnier, Caroline, Varon, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275086/
https://www.ncbi.nlm.nih.gov/pubmed/30380687
http://dx.doi.org/10.3390/ijms19113388
_version_ 1783377759331942400
author Bouriez, Damien
Giraud, Julie
Gronnier, Caroline
Varon, Christine
author_facet Bouriez, Damien
Giraud, Julie
Gronnier, Caroline
Varon, Christine
author_sort Bouriez, Damien
collection PubMed
description Gastric cancer (GC) is the third leading cause of cancer-related death worldwide with a five-year survival rate of around 25%, and 4% when diagnosed at a metastatic stage. Cancer stem cells (CSC) have recently been characterized as being responsible for resistance to radio/chemotherapies and metastasis formation, opening up perspectives for new targeted therapies. Those CSCs express biomarkers such as cluster of differentiation 44 (CD44) and display high aldehyde dehydrogenase activity that converts vitamin A-derived retinal into retinoic acids. All-trans retinoic acid (ATRA), which has pro-differentiating properties, has revolutionized the prognosis of acute promyelotic leukemia by increasing its remission rate from 15% to 85%. Recent studies have started to show that ATRA also has an anti-tumoral role on solid cancers such as GC. The purpose of this review is therefore to summarize the work that evaluated the effects of ATRA in GC and to evaluate whether its anti-cancerous action involves gastric CSCs targeting. It has been demonstrated that ATRA can block the cell cycle, enhance apoptosis, and decrease gastric CSCs properties in GC cell lines, tumorspheres, and patient-derived xenograft mice models. Therefore, retinoids and new synthetic retinoids seem to be a promising step forward in targeted therapy of gastric CSC in combination with existing chemotherapies. Future studies should probably focus on these points.
format Online
Article
Text
id pubmed-6275086
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62750862018-12-15 Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review Bouriez, Damien Giraud, Julie Gronnier, Caroline Varon, Christine Int J Mol Sci Review Gastric cancer (GC) is the third leading cause of cancer-related death worldwide with a five-year survival rate of around 25%, and 4% when diagnosed at a metastatic stage. Cancer stem cells (CSC) have recently been characterized as being responsible for resistance to radio/chemotherapies and metastasis formation, opening up perspectives for new targeted therapies. Those CSCs express biomarkers such as cluster of differentiation 44 (CD44) and display high aldehyde dehydrogenase activity that converts vitamin A-derived retinal into retinoic acids. All-trans retinoic acid (ATRA), which has pro-differentiating properties, has revolutionized the prognosis of acute promyelotic leukemia by increasing its remission rate from 15% to 85%. Recent studies have started to show that ATRA also has an anti-tumoral role on solid cancers such as GC. The purpose of this review is therefore to summarize the work that evaluated the effects of ATRA in GC and to evaluate whether its anti-cancerous action involves gastric CSCs targeting. It has been demonstrated that ATRA can block the cell cycle, enhance apoptosis, and decrease gastric CSCs properties in GC cell lines, tumorspheres, and patient-derived xenograft mice models. Therefore, retinoids and new synthetic retinoids seem to be a promising step forward in targeted therapy of gastric CSC in combination with existing chemotherapies. Future studies should probably focus on these points. MDPI 2018-10-29 /pmc/articles/PMC6275086/ /pubmed/30380687 http://dx.doi.org/10.3390/ijms19113388 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bouriez, Damien
Giraud, Julie
Gronnier, Caroline
Varon, Christine
Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
title Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
title_full Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
title_fullStr Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
title_full_unstemmed Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
title_short Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review
title_sort efficiency of all-trans retinoic acid on gastric cancer: a narrative literature review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275086/
https://www.ncbi.nlm.nih.gov/pubmed/30380687
http://dx.doi.org/10.3390/ijms19113388
work_keys_str_mv AT bouriezdamien efficiencyofalltransretinoicacidongastriccanceranarrativeliteraturereview
AT giraudjulie efficiencyofalltransretinoicacidongastriccanceranarrativeliteraturereview
AT gronniercaroline efficiencyofalltransretinoicacidongastriccanceranarrativeliteraturereview
AT varonchristine efficiencyofalltransretinoicacidongastriccanceranarrativeliteraturereview